biological source
goat
conjugate
FITC conjugate
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable, immunohistochemistry: suitable
shipped in
wet ice
Quality Level
Immunogen
Hexon from adenovirus type 5.
Application
Anti-Adenovirus Antibody, FITC-conjugated is an antibody against Adenovirus for use in IF, IH.
Direct FA staining of target antigens in a permissive tissue culture system. Suggested dilution: 1:10-1:50. Acetone fixation of the antigen source is recommended prior to staining.
Optimal working dilutions must be determined by end user
Optimal working dilutions must be determined by end user
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Biochem/physiol Actions
Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells
Physical form
IgG fraction conjugated to FITC. In PBS (0.01 M, pH 7.2) containing 10 mg/mL BSA and 0.1% sodium azide
Preparation Note
Maintain at 2-8°C for 3 months or at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. Store under subdued light.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Sacha Robert et al.
Viruses, 16(4) (2024-04-27)
Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically
In situ adenovirus vaccination engages T effector cells against cancer.
Sebastian Tuve, Ying Liu, Khajornsak Tragoolpua, Jeffrey Daniel Jacobs et al.
Vaccine null
Comparison of adenoviruses from species B, C, E, and F after intravenous delivery.
Daniel Stone, Ying Liu, Zong-Yi Li, Sebastian Tuve, Robert Strauss, Andre Lieber
Molecular Therapy null
Yoshihiko Kakiuchi et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(10), 2920-2930 (2021-05-24)
Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301)
A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication.
Kathrin Bernt, Min Liang, Xun Ye, Shaoheng Ni, Zong-Yi Li, Sheng Long Ye, Fang Hu, Andre Lieber
Journal of virology null
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持